title: The role of HBsAg levels in the current management of chronic HBV infection.
abstract: Chronic hepatitis B virus (HBV) infection can result in liver cirrhosis, hepatic decompensation, and hepatocellular carcinoma (HCC). However, the natural course of the disease is highly dynamic and not every patient requires therapy. The challenges for optimal management are who to treat, which therapeutic regimen to use, and when to begin or stop treatment. Constant monitoring is mandatory to predict the natural course and guide treatment decisions. Surrogate markers for baseline and on treatment decisions are needed. Besides HBV DNA, hepatitis B surface antigen levels also proved to be useful to help judge the natural course and guide treatment. High levels of HBsAg are suggestive of low fibrosis and immune tolerance in hepatitis B e antigen (HBeAg) positive patients; whereas low levels of HBsAg indicate a lower risk for HCC and inactive carrier state in HBeAg negative patients. Data also support the possible use of HBsAg levels as an on-treatment response marker. So far, the best evidence exists for treatment with interferon (IFN)-α where lack of HBsAg decline after 12 weeks is associated with non-response. Thus, stopping rules after 12 weeks therapy could be established for HBeAg positive as well as for HBeAg negative patients. However, the positive predictive value for achieving sustained response is still vague. The value of HBsAg monitoring is less clear during treatment with nucleos(t)ide analogues (NA) but it can be a useful marker for new concepts such as stopping NA or add-on IFN strategies. Currently, several studies are underway to validate HBsAg in these settings.
authors.affiliation: Department of Gastroenterology, Hepatology and Endocrinology, Medical School Hannover, Germany.
authors.forename: Christoph
authors.initials: C
authors.lastname: Höner Zu Siederdissen
authors.affiliation: Department of Gastroenterology, Hepatology and Endocrinology, Medical School Hannover, Germany.
authors.forename: Markus
authors.initials: M
authors.lastname: Cornberg
keywords: Chronic hepatitis B; hepatitis B surface antigen; interferon α; nucleos(t)ide analogues
references.citation: Scand J Gastroenterol. 2009;44(12):1487-90
references.pmid: 19900055
references.citation: J Virol Methods. 2004 Feb;115(2):217-22
references.pmid: 14667538
references.citation: Lancet. 2013 Feb 9;381(9865):468-75
references.pmid: 23234725
references.citation: Am J Gastroenterol. 1998 Jun;93(6):896-900
references.pmid: 9647014
references.citation: J Clin Virol. 2011 Apr;50(4):292-6
references.pmid: 21273117
references.citation: Hepatology. 2006 Oct;44(4):915-24
references.pmid: 17006908
references.citation: Hepatology. 2012 Jul;56(1):67-75
references.pmid: 22307831
references.citation: J Hepatol. 2011 Mar;54(3):449-54
references.pmid: 21112655
references.citation: Hepatology. 2009 Apr;49(4):1151-7
references.pmid: 19115222
references.citation: PLoS One. 2012;7(8):e43087
references.pmid: 22916211
references.citation: Aliment Pharmacol Ther. 2010 Dec;32(11-12):1323-31
references.pmid: 21050234
references.citation: PLoS One. 2012;7(8):e43143
references.pmid: 22905219
references.citation: Clin Vaccine Immunol. 2011 Nov;18(11):1943-50
references.pmid: 21880853
references.citation: J Hepatol. 2013 Jun;58(6):1089-95
references.pmid: 23369792
references.citation: Hepatology. 2006 Jan;43(1):100-7
references.pmid: 16323213
references.citation: J Hepatol. 2002 Apr;36(4):543-6
references.pmid: 11943427
references.citation: N Engl J Med. 2004 Sep 16;351(12):1206-17
references.pmid: 15371578
references.citation: J Hepatol. 2010 Apr;52(4):514-22
references.pmid: 20207438
references.citation: Antivir Ther. 2012;17(1):9-17
references.pmid: 22267464
references.citation: AIDS. 2012 May 15;26(8):939-49
references.pmid: 22333748
references.citation: N Engl J Med. 2011 Jan 27;364(4):322-31
references.pmid: 21268724
references.citation: Gastroenterology. 1999 Nov;117(5):1229-33
references.pmid: 10535887
references.citation: Liver Int. 2006 Sep;26(7):805-10
references.pmid: 16911462
references.citation: J Hepatol. 2010 Apr;52(4):508-13
references.pmid: 20206400
references.citation: J Hepatol. 2008 Nov;49(5):688-94
references.pmid: 18490077
references.citation: J Infect Dis. 2011 Aug 1;204(3):415-8
references.pmid: 21742840
references.citation: Hepatology. 2011 Nov;54(5):1591-9
references.pmid: 22045673
references.citation: Hepatology. 2004 Mar;39(3):804-10
references.pmid: 14999700
references.citation: J Hepatol. 2013 May;58(5):853-60
references.pmid: 23246508
references.citation: Nat Rev Gastroenterol Hepatol. 2010 Jan;7(1):31-40
references.pmid: 20051970
references.citation: J Viral Hepat. 2009 Dec;16(12):883-94
references.pmid: 19566789
references.citation: Hepatology. 2013 Jul;58(1):98-107
references.pmid: 23213040
references.citation: N Engl J Med. 2013 May 16;368(20):1907-17
references.pmid: 23675659
references.citation: J Clin Virol. 2012 May;54(1):93-5
references.pmid: 22365367
references.citation: Antivir Ther. 2007;12(3):381-8
references.pmid: 17591028
references.citation: Hepatology. 2010 Oct;52(4):1232-41
references.pmid: 20648555
references.citation: N Engl J Med. 1996 May 30;334(22):1422-7
references.pmid: 8618580
references.citation: Hepatology. 2006 Feb;43(2 Suppl 1):S182-93
references.pmid: 16447260
references.citation: Antivir Ther. 2013;18(7):895-904
references.pmid: 23639931
references.citation: Lancet. 2005 Jan 8-14;365(9454):123-9
references.pmid: 15639293
references.citation: Lancet. 2009 Feb 14;373(9663):582-92
references.pmid: 19217993
references.citation: J Hepatol. 2012 May;56(5):1006-1011
references.pmid: 22245886
references.citation: Hepatology. 2010 Nov;52(5):1611-20
references.pmid: 20931556
references.citation: J Hepatol. 2013 Jun;58(6):1258-9
references.pmid: 23318602
references.citation: J Hepatol. 2006 Oct;45(4):529-38
references.pmid: 16879891
references.citation: Viral Immunol. 2012 Dec;25(6):442-7
references.pmid: 23131018
references.citation: Gut. 2003 Mar;52(3):420-4
references.pmid: 12584227
references.citation: Hepatology. 2010 Aug;52(2):454-61
references.pmid: 20683945
references.citation: Hepatology. 2006 Sep;44(3):675-84
references.pmid: 16941693
references.citation: Gastroenterology. 2009 Jun;136(7):2169-2179.e1-4
references.pmid: 19303414
references.citation: JAMA. 2006 Jan 4;295(1):65-73
references.pmid: 16391218
references.citation: J Hepatol. 2011 Nov;55(5):1121-31
references.pmid: 21718667
references.citation: Hepatology. 2013 Sep;58(3):872-80
references.pmid: 23553752
references.citation: Gastroenterology. 2012 Oct;143(4):963-73.e9
references.pmid: 22796241
references.citation: N Engl J Med. 2005 Jun 30;352(26):2682-95
references.pmid: 15987917
references.citation: Int J Epidemiol. 2005 Dec;34(6):1329-39
references.pmid: 16249217
references.citation: J Hepatol. 2013 Apr;58(4):676-83
references.pmid: 23219442
references.citation: J Clin Virol. 2010 May;48(1):22-6
references.pmid: 20233672
references.citation: Gastroenterology. 2012 Sep;143(3):629-636.e1
references.pmid: 22659218
references.citation: J Viral Hepat. 2001 Sep;8(5):311-21
references.pmid: 11555188
references.citation: Hepatology. 2010 Oct;52(4):1251-7
references.pmid: 20830787
references.citation: J Clin Virol. 2011 Jul;51(3):175-8
references.pmid: 21592855
references.citation: Gastroenterology. 2010 Aug;139(2):483-90
references.pmid: 20451520
references.citation: Antivir Ther. 2011;16(8):1249-57
references.pmid: 22155906
references.citation: Hepatology. 2010 Sep;52(3):886-93
references.pmid: 20683932
references.citation: Gastroenterology. 2010 Aug;139(2):491-8
references.pmid: 20381492
references.citation: Antivir Ther. 2011;16(6):915-24
references.pmid: 21900724
references.citation: Hepatology. 2009 May;49(5 Suppl):S72-84
references.pmid: 19399801
references.citation: J Hepatol. 2011 Jul;55(1):61-8
references.pmid: 21145875
references.citation: J Hepatol. 2012 Jul;57(1):167-85
references.pmid: 22436845
references.citation: J Hepatol. 2010 Aug;53(2):348-56
references.pmid: 20483498